Patents by Inventor Beth Stevens
Beth Stevens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220348590Abstract: The present disclosure describes compounds of the formula: (I), (II), (III), (IV), (V). The compounds described herein may be cyclooxygenase (COX) (e.g., cyclooxygenase 2 (COX2)) inhibitors. The compounds may be radiolabeled. The compounds (e.g., radiolabeled compounds) may be useful (e.g., as positron emission tomography (PET) imaging agents) for diagnosing a disease. The compounds may also be useful for treating or preventing a disease. The present disclosure also describes pharmaceutical compositions and kits including the compounds; and methods of using the compounds.Type: ApplicationFiled: September 10, 2020Publication date: November 3, 2022Applicants: The Board Institute, Inc., The General Hospital Corporation, Children's Medical Center Corporation, President and Fellows of Harvard CollegeInventors: Florence Fevrier Wagner, Michel Weiwer, Arthur J. Campbell, Joshua R. Sacher, Antoine Bigot, Agathe Fayet, Besnik Bajrami, Jacob Hooker, Michael Placzek, Beth A. Stevens, Daniel Wilton, Steven McCarroll
-
Patent number: 10330671Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease.Type: GrantFiled: November 11, 2016Date of Patent: June 25, 2019Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ben A. Barres, Beth A. Stevens
-
Patent number: 10240156Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including treating and preventing neurodegenerative diseases such as Alzheimer's disease.Type: GrantFiled: July 28, 2016Date of Patent: March 26, 2019Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ben A. Barres, Alexander H. Stephan, Beth A. Stevens
-
Publication number: 20190033329Abstract: The invention provides methods of treating schizophrenia in a subject, including for example, administering to the subject an agent that inhibits expression or activity of a C4A polynucleotide or polypeptide. The invention also provides methods of identifying a subject having or at risk of developing schizophrenia involving measuring or detecting an alteration in the level, copy number, and/or sequence of complement component C4A or complement component C4B relative to a reference.Type: ApplicationFiled: January 24, 2017Publication date: January 31, 2019Applicants: PRESIDENT AND FELLOWS OF HARVARD COLLEGE, CHILDREN'S MEDICAL CENTER CORPORATIONInventors: STEVEN A. MCCARROLL, ASWIN SEKAR, MICHAEL C. CARROLL, BETH STEVENS
-
Publication number: 20170059559Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease.Type: ApplicationFiled: November 11, 2016Publication date: March 2, 2017Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ben A. Barres, Beth A. Stevens
-
Patent number: 9493555Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease.Type: GrantFiled: March 15, 2016Date of Patent: November 15, 2016Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ben A. Barres, Beth A. Stevens
-
Publication number: 20160326534Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including treating and preventing neurodegenerative diseases such as Alzheimer's disease.Type: ApplicationFiled: July 28, 2016Publication date: November 10, 2016Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ben A. Barres, Alexander H. Stephen, Beth A. Stevens
-
Publication number: 20160327572Abstract: The present invention provides CSF protein-based biomarkers and biomarker combinations that are useful in diagnosing dementia or a dementia related neurological disorder a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as Alzheimer's dementia, non-Alzheimer's dementia, as Progressive supranuclear palsy (PSP), non-PSP dementia or normal. In some aspects, the invention relates to methods useful for diagnosing, classifying, and profiling dementia or a dementia related neurological disorder a patient.Type: ApplicationFiled: January 6, 2015Publication date: November 10, 2016Inventors: Omar S. Barnaby, Judith Steen, Beth Stevens, Hanno Steen, Soyon Y. Hong
-
Patent number: 9480658Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including treating and preventing neurodegenerative diseases such as Alzheimer's disease.Type: GrantFiled: August 15, 2012Date of Patent: November 1, 2016Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ben A. Barres, Alexander H. Stephan, Beth A. Stevens
-
Patent number: 9388238Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease.Type: GrantFiled: June 26, 2015Date of Patent: July 12, 2016Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ben A. Barres, Beth A. Stevens
-
Patent number: 9382314Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease.Type: GrantFiled: June 26, 2015Date of Patent: July 5, 2016Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ben A. Barres, Beth A. Stevens
-
Patent number: 9382313Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease.Type: GrantFiled: June 26, 2015Date of Patent: July 5, 2016Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ben A. Barres, Beth A. Stevens
-
Publication number: 20160185844Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease.Type: ApplicationFiled: March 15, 2016Publication date: June 30, 2016Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ben A. Barres, Beth A. Stevens
-
Publication number: 20160159890Abstract: This invention relates generally to methods of treatment for neurodegenerative diseases such as Alzheimer's disease, Alzheimer's-related diseases, and Huntington's disease, and more specifically to methods involving the inhibition of the classical pathway of complement activation.Type: ApplicationFiled: January 5, 2016Publication date: June 9, 2016Inventors: Arnon Rosenthal, Michael Leviten, Beth A. Stevens, Soyon Hong, Daniel Wilton
-
Publication number: 20150368325Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease.Type: ApplicationFiled: June 26, 2015Publication date: December 24, 2015Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ben A. Barres, Beth A. Stevens
-
Publication number: 20150368326Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease.Type: ApplicationFiled: June 26, 2015Publication date: December 24, 2015Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ben A. Barres, Beth A. Stevens
-
Publication number: 20150368324Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease.Type: ApplicationFiled: June 26, 2015Publication date: December 24, 2015Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ben A. Barres, Beth A. Stevens
-
Patent number: 9149444Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease.Type: GrantFiled: December 14, 2011Date of Patent: October 6, 2015Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ben A. Barres, Beth A. Stevens
-
Publication number: 20120328601Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including treating and preventing neurodegenerative diseases such as Alzheimer's disease.Type: ApplicationFiled: August 15, 2012Publication date: December 27, 2012Inventors: Ben A. Barres, Alexander H. Stephan, Beth A. Stevens
-
Publication number: 20120195880Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease.Type: ApplicationFiled: December 14, 2011Publication date: August 2, 2012Inventors: Ben A. Barres, Beth A. Stevens